Q/C Technologies, Inc.
QCLS- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001321834
No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Q/C Technologies, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 23 | 1 | 20 | −2 |
| Shares | 62.0K | 3.80K | 37.2K | −21.0K (−36.0%) |
| Value | $114.6K | $7.00K | $60.3K | −$47.3K (−44.0%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Q/C Technologies, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 3,803 | $6.16K | 0.00% |
| Bryn Mawr Trust Co | 134 | $217 | 0.00% |
| ORG Wealth Partners, LLC | 34 | $55 | 0.00% |
| Sound Income Strategies, LLC | 1 | $2 | 0.00% |
Sold out (6)
Institutions that held Q/C Technologies, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| UBS Group AG | 15,822 | $29.1K |
| Virtu Financial LLC | 11,688 | $22.0K |
| Redwood Wealth Management Group, LLC | 50 | $92 |
| Mather Group, LLC. | 17 | $41 |
| Qube Research & Technologies Ltd | 3 | $6 |
| Anchor Investment Management, LLC | 1 | $2 |
Not filed for Q3 2024 yet (1)
Institutions that held Q/C Technologies, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 3,803 | $7.00K |